Beck RW, Cleary PA, Anderson MM, Jr., Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–8. https://doi.org/10.1056/nejm199202273260901.

Group IONDTS. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Archives Ophthalmol (Chicago, Ill : 1960). 1996;114(11):1366–74. https://doi.org/10.1001/archopht.1996.01100140566007.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (London, England). 2004;364(9451):2106–12. https://doi.org/10.1016/s0140-6736(04)17551-x.

Article  CAS  PubMed  Google Scholar 

O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13(2):211–7. https://doi.org/10.1038/nm1488.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89–100. https://doi.org/10.1016/s1474-4422(22)00187-9.

Article  CAS  PubMed  Google Scholar 

Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225–31. https://doi.org/10.1016/j.jns.2018.11.029.

Article  CAS  PubMed  Google Scholar 

Zhou H, Zhao S, Yin D, Chen X, Xu Q, Chen T, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol. 2016;263(7):1382–9. https://doi.org/10.1007/s00415-016-8155-7.

Article  CAS  PubMed  Google Scholar 

Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica Nature reviews Disease primers. 2020;6(1):85. https://doi.org/10.1038/s41572-020-0214-9.

Article  PubMed  Google Scholar 

• Biousse V, Danesh-Meyer HV, Saindane AM, Lamirel C, Newman NJ. Imaging of the optic nerve: technological advances and future prospects. Lancet Neurol. 2022;21(12):1135–50. https://doi.org/10.1016/s1474-4422(22)00173-9. An important review of the modern diagnostic modalities available to aid in the diagnosis of various optic neuropathies, with emphasis on recent updates. The modalities discussed included OCT, ultrasound, fundus photography, CT, and MRI.

Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8–15. https://doi.org/10.1016/j.ajo.2018.07.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Multiple Sclerosis (Houndmills, Basingstoke, England). 2020;26(7):806–14. https://doi.org/10.1177/1352458519845112.

Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain J Neurol. 2017;140(12):3128–38. https://doi.org/10.1093/brain/awx276.

Article  Google Scholar 

Winter A, Chwalisz B. MRI characteristics of NMO, MOG and MS related optic neuritis. Semin Ophthalmol. 2020;35(7–8):333–42. https://doi.org/10.1080/08820538.2020.1866027.

Article  PubMed  Google Scholar 

Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, et al. Population-Based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol. 2020;220:110–4. https://doi.org/10.1016/j.ajo.2020.07.014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hickman SJ, Petzold A. Update on optic neuritis: an international view. Neuro-ophthalmology (Aeolus Press). 2022;46(1):1–18. https://doi.org/10.1080/01658107.2021.1964541.

Article  PubMed  Google Scholar 

Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4–IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmology. 2018;136(4):419–22. https://doi.org/10.1001/jamaophthalmol.2017.6757.

Article  PubMed  PubMed Central  Google Scholar 

Miller H. Clinical applications of steroid therapy in neurology. Proc R Soc Med. 1961;54(5):571–5.

CAS  PubMed  Google Scholar 

Rawson MD, Liversedge LA. Treatment of retrobulbar neuritis with corticotrophin. Lancet (London, England). 1969;2(7613):222. https://doi.org/10.1016/s0140-6736(69)91469-x.

Article  CAS  PubMed  Google Scholar 

Bowden AN, Bowden PM, Friedmann AI, Perkin GD, Rose FC. A trial of corticotrophin gelatin injection in acute optic neuritis. J Neurol Neurosurg Psychiatry. 1974;37(8):869–73. https://doi.org/10.1136/jnnp.37.8.869.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gould ES, Bird AC, Leaver PK, McDonald WI. Treatmenf of optic neuritis by retrobulbar injection of triamcinolone. BMJ. 1977;1(6075):1495–7. https://doi.org/10.1136/bmj.1.6075.1495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beck RW, Cleary PA, Backlund J-yC. The course of visual recovery after optic neuritis: experience of the optic neuritis treatment trial. Ophthalmology. 1994;101(11):1771–8. https://doi.org/10.1016/S0161-6420(94)31103-1.

Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329(24):1764–9. https://doi.org/10.1056/nejm199312093292403.

Group ONS. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology. 1997;49(5):1404–13. https://doi.org/10.1212/wnl.49.5.1404.

Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. Jama. 1993;269(16):2110–2.

Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. 2018;75(6):690–6. https://doi.org/10.1001/jamaneurol.2018.0024.

Article  PubMed  PubMed Central  Google Scholar 

• Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267(12):3565–77. https://doi.org/10.1007/s00415-020-10026-y. This paper provides an international perspective of the treatment approaches used for MOGAD-associated optic neuritis. This is particularly useful given that both the awareness and understanding of this type of optic neuritis is still growing and there is thus wide variability in treatment approaches.

Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome. Multiple sclerosis and related disorders. 2019;27:127–30. https://doi.org/10.1016/j.msard.2018.10.013.

Article  PubMed  Google Scholar 

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–16. https://doi.org/10.1002/ana.24554.

Article  CAS  PubMed  Google Scholar 

Shindler KS, Ventura E, Dutt M, Rostami A. Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp Eye Res. 2008;87(3):208–13. https://doi.org/10.1016/j.exer.2008.05.017.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osinga E, van Oosten B, de Vries-Knoppert W, Petzold A. Time is vision in recurrent optic neuritis. Brain Res. 2017;1673:95–101. https://doi.org/10.1016/j.brainres.2017.08.012.

Article  CAS  PubMed  Google Scholar 

Plant GT, Sibtain NA, Thomas D. Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Multiple Sclerosis Int. 2011;2011:815068. https://doi.org/10.1155/2011/815068.

Nakamura M, Nakazawa T, Doi H, Hariya T, Omodaka K, Misu T, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2010;248(12):1777–85. https://doi.org/10.1007/s00417-010-1344-7.

Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurology(R) Neuroimmunol neuroinflammation. 2019;6(4):e572. https://doi.org/10.1212/nxi.0000000000000572.

Deschamps R, Gueguen A, Parquet N, Saheb S, Driss F, Mesnil M, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol. 2016;263(5):883–7. https://doi.org/10.1007/s00415-016-8073-8.

Article  PubMed  Google Scholar 

Skorupka N, Miclea A, Jalowiec KA, Bocksrucker C, Kamber N, Chan A, et al. Visual Outcomes of plasma exchange treatment of steroid-refractory optic neuritis: a retrospective monocentric analysis. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2019;46(6):417–22. https://doi.org/10.1159/000504027.

Article  PubMed  Google Scholar 

•• Galetta K, Ryan S, Manzano G, Chibnik LB, Balaban D, Prasad S, et al. Treatment outcomes of first-ever episode of severe optic neuritis. Mult Scler Relat Disord. 2022;66:104020. https://doi.org/10.1016/j.msard.2022.104020. This paper provides outcome data for a common real-world scenario: undifferentiated, first-ever episodes of optic neuritis. With growing awareness of MS-, MOGAD-, and NMOSD-associated subtypes of optic neuritis, clinicians must consider various treatment modalities and their respective timing in the context of each of these subtypes.

Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58(1):143–6. https://doi.org/10.1212/wnl.58.1.143.

Article  CAS  PubMed  Google Scholar 

Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler J. 2009;15(4):487–92. https://doi.org/10.1177/1352458508100837.

Article  CAS  Google Scholar 

Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630. https://doi.org/10.1155/2012/787630.

Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Archives Ophthalmol (Chicago, Ill : 1960). 2012;130(7):858–62. https://doi.org/10.1001/archophthalmol.2012.1126.

Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012;126(2):103–8. https://doi.org/10.1111/j.1600-0404.2011.01612.x.

Article  CAS  PubMed  Google Scholar 

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurology(R) Neuroimmunol Neuroinflammation. 2018;5(6):e504. https://doi.org/10.1212/nxi.0000000000000504.

•• Songthammawat T, Srisupa - Olan T, Siritho S, Kittisares K, Jitprapaikulsan J, Sathukitchai C, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020;38:101506. https://doi.org/10.1016/j.msard.2019.101506. Prior to this study, there was limited data available on the importance of timing for PLEX. This paper provides a comparison between the sequential and simultaneous implementation of IVMP and PLEX.

Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56(11):1514–22. https://doi.org/10.1212/wnl.56.11.1514.

Article  CAS  PubMed  Google Scholar